METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.
1 . A method of treating cardiovascular disease in a human in need thereof which comprises the in vivo administration of a therapeutically effective amount of a compound selected from
3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid,
or a pharmaceutically acceptable salt thereof, and
3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl,
or a pharmaceutically acceptable salt thereof;
to such human.
2 . A method according to claim 1 wherein the compound is 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
3 . A method according to claim 1 wherein the compound is 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid bis-(monoethanolamine).
4 . A method according to claim 3 wherein the cardiovascular disease is myocardial infarction.
5 . A method according to claim 3 wherein the human is in need of treatment for repair of cardiovascular tissue.
6 . A method according to claim 3 wherein the human is in need of tissue reparation for cardiovascular disorders.
7 . A method according to claim 6 wherein the cardiovascular disorder occurred during cardiac bypass surgery.
8 . A method according to claim 6 wherein the cardiovascular disorder occurred during heart surgery.
9 . A method according to claim 8 wherein the heart surgery was heart transplant surgery.
10 . A method according to claim 8 wherein the compound is administered prior to heart surgery.
11 . A method according to claim 3 wherein the compound is administered orally.
12 . A method according to claim 3 wherein the compound is administered parenterally.
13 . A method according to claim 11 wherein the compound is administered in tablet form.
14 . A method according to claim 3 wherein the cardiovascular disease is due to viral, fungal, microbial or parasitic infection.
15 . A method according to claim 3 wherein the cardiovascular disease is due to surgical procedures.
16 . A method according to claim 3 wherein the cardiovascular disease is due to treatment with antiviral or antibiotic agents.
17 . A method according to claim 13 wherein the tablet contains an amount from 0.05 to 3500 mg of active compound.
18 . A method according to claim 13 wherein the tablet contains an amount from 0.1 to 3000 mg of active compound.
19 . A method according to claim 13 wherein the tablet contains 20 mg of active compound.
20 . A method according to claim 3 wherein the cardiovascular disease is due to treatment with a pharmaceutically active agent.
21 . A method according to claim 3 wherein the cardiovascular disease is due to treatment with an anti-neoplastic agent.
22 . A method according to claim 21 wherein the cardiovascular disease is due to treatment with a chemotherapeutic agent.
23 . A method according to claim 21 wherein the cardiovascular disease is due to treatment with a tyrosine kinase inhibiting compound.
24 . A method according to claim 21 wherein the cardiovascular disease is due to treatment at least one compound selected from: Doxorubicin, herceptin, Gleevac, Sprycel, Tasigna, Sutent, Nexavar, Avastin, Tykerb, Iressa, Tarceva, Erbitux and Panitumumab.
25 . A method according to claim 3 wherein the cardiovascular disease is due to treatment with radiation therapy.
26 . A method according to claim 20 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
27 . A method according to claim 20 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
28 . A method according to claim 20 wherein the compound is administered in a tablet that contains 20 mg of active compound.
29 . A method according to claim 21 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
30 . A method according to claim 21 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
31 . A method according to claim 21 wherein the compound is administered in a tablet that contains 20 mg of active compound.
32 . A method according to claim 4 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
33 . A method according to claim 4 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
34 . A method according to claim 4 wherein the compound is administered in a tablet that contains 20 mg of active compound.
35 . A method according to claim 3 wherein the compound is administered prior to heart surgery.
36 . A method according to claim 3 wherein the compound is administered prior to treatment with a pharmaceutically active agent.
37 . A method according to claim 3 wherein the compound is administered prior to treatment with an anti-neoplastic agent.
38 . A method according to claim 3 wherein the compound is administered prior to treatment with a chemotherapeutic agent.
39 . A method according to claim 3 wherein the compound is administered prior to treatment with a tyrosine kinase inhibiting compound.
40 . A method according to claim 20 wherein the pharmaceutically active agent is a heart imaging drug.
41 . (Previously Presented A method according to claim 40 wherein the heart imaging drug is selected from: Definity and Optison.
42 . A method according to claim 40 wherein the tablet contains an amount from 0.05 to 3500 mg of active compound.
43 . A method according to claim 41 wherein the tablet contains an amount from 0.1 to 3000 mg of active compound.
44 . A method according to claim 40 wherein the tablet contains 20 mg of active compound.
45 . A method according to claim 3 wherein the cardiovascular disease is due to exposure to radiation.
46 . A method according to claim 3 wherein the compound is administered prior to treatment with a heart imaging drug.